A
A
A
Patient / Consumer
Know more about Medicines Regulation Know more about access to medicines which do not have a Marketing Authorisation Report a Side Effect Biological and Biosimilar Medicinal Products How we monitor the safety of medicines Know more about the Medicines Supply Chain Know more about Use of Medicines Information Leaflets on Medicines Search for your Medicines
Industry
Pharmaceutical Activities and Inspections Product Quality Defects Reporting Scientific Advice Advertising Registering a product Pharmacovigilance Fees
Health Care Professionals
Search Authorised Medicines in Malta Adverse Drug Reaction Reporting How we monitor the safety of medicinal products Safety Information Clinical Trials Product Quality Defects Reporting Medicines supply chain and regulation Advertising
Home / News Archive / News Details

Medical Product Alert N°3/2026: Falsified DARZALEX (daratumumab)

Published: 04 Jul 2026

 

Medical Product Alert N°3/2026: Falsified DARZALEX (daratumumab)

Falsified DARZALEX (daratumumab) identified in the WHO regions of the Americas and South-East Asia

 

For more information please click here.

 

 

 

 

Previous News Update
Next News Update

Latest News Updates

04 Jul 2026

Medical Product Alert N°3/2026: Falsified DARZALEX (daratumumab)

Find out more

Latest News Updates

04 Jul 2026

Medical Product Alert N°3/2026: Falsified DARZALEX (daratumumab)

Find out more

Latest News Updates

25 Jun 2026

Medical Product Alert N°2/2026

Medical Product Alert N°2/2026: Falsified JAKAVI (ruxolitinib) Falsified JAKAVI (ruxolitinib) identified in the WHO Eastern Mediterranean and European regions

Find out more